New York Post

New ‘off-the-shelf’ pancreatic cancer therapy able to hunt down tumors — even after they spread: study

Scientists at UCLA have developed an “off-the-shelf” cell-based immunotherapy that was able to track down and kill pancreatic cancer cells even after they had spread to other organs. In a mouse study, ...
Business Insider

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting

ST. LOUIS, Mo., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological ...
STAT

Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
FierceBiotech

ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial

ImmunityBio has reported ongoing complete responses of up to 15 months in two recipients of its CAR-NK cell therapy, leading the biopharma to talk up the prospects of the off-the-shelf blood cancer ...